On 1 April 2020, Pharmaceutical Benefits Scheme (PBS) announced changes to the general schedule for the treatment of hepatitis C. Key changes are listed below:

  • Removal of the requirement to provide the hepatitis C virus genotype at the time of application
  • Removal of the population criteria: Patient must be aged 18 years or older

You can view the updated General Statement for Drugs for the Treatment of Hepatitis C here: http://www.pbs.gov.au/info/healthpro/explanatory-notes/general-statement-hep-c

Pangenotypic treatments are suitable for all genotypes of hepatitis C and simplify prescribing and treatment.

ASHM currently offers a full suite of hepatitis C training. You can find upcoming courses here: https://ashm.org.au/HCV/training/